203 related articles for article (PubMed ID: 37992168)
21. Cellular functions of the protein kinase ATM and their relevance to human disease.
Lee JH; Paull TT
Nat Rev Mol Cell Biol; 2021 Dec; 22(12):796-814. PubMed ID: 34429537
[TBL] [Abstract][Full Text] [Related]
22. The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication.
Ariumi Y; Kuroki M; Dansako H; Abe K; Ikeda M; Wakita T; Kato N
J Virol; 2008 Oct; 82(19):9639-46. PubMed ID: 18667510
[TBL] [Abstract][Full Text] [Related]
23. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
[TBL] [Abstract][Full Text] [Related]
24. Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic.
Priya B; Ravi S; Kirubakaran S
Drug Discov Today; 2023 Aug; 28(8):103662. PubMed ID: 37302542
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.
Vecchio D; Frosina G
Curr Drug Targets; 2016; 17(2):139-53. PubMed ID: 25382204
[TBL] [Abstract][Full Text] [Related]
26. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
27. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
28. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
29. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
Sundar R; Miranda S; Rodrigues DN; Chénard-Poirier M; Dolling D; Clarke M; Figueiredo I; Bertan C; Yuan W; Ferreira A; Chistova R; Boysen G; Perez DR; Tunariu N; Mateo J; Wotherspoon A; Chau I; Cunningham D; Valeri N; Carreira S; de Bono J
Clin Colorectal Cancer; 2018 Dec; 17(4):280-284. PubMed ID: 30042009
[TBL] [Abstract][Full Text] [Related]
30. Targeting ATR in Cancer Medicine.
Salguero C; Valladolid C; Robinson HMR; Smith GCM; Yap TA
Cancer Treat Res; 2023; 186():239-283. PubMed ID: 37978140
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic Analysis of ATM Protein Kinase in DNA Double-Strand Break Formation and Repair.
Mian E; Wiesmüller L
Methods Mol Biol; 2017; 1599():317-334. PubMed ID: 28477129
[TBL] [Abstract][Full Text] [Related]
32. Quantitative phosphoproteomics of the ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia-mutated and rad3-related (ATR) dependent DNA damage response in Arabidopsis thaliana.
Roitinger E; Hofer M; Köcher T; Pichler P; Novatchkova M; Yang J; Schlögelhofer P; Mechtler K
Mol Cell Proteomics; 2015 Mar; 14(3):556-71. PubMed ID: 25561503
[TBL] [Abstract][Full Text] [Related]
33. ATR Inhibition in Advanced Urothelial Carcinoma.
Leibrandt RC; Tu MJ; Yu AM; Lara PN; Parikh M
Clin Genitourin Cancer; 2023 Apr; 21(2):203-207. PubMed ID: 36604210
[TBL] [Abstract][Full Text] [Related]
34. RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity.
Maybee DV; Psaras AM; Brooks TA; Ali MAM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233063
[TBL] [Abstract][Full Text] [Related]
35. ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines.
Wikiniyadhanee R; Lerksuthirat T; Stitchantrakul W; Chitphuk S; Takeda S; Dejsuphong D
Biomed Res Int; 2023; 2023():7891753. PubMed ID: 36794257
[TBL] [Abstract][Full Text] [Related]
36. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
37. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
Armstrong SA; Schultz CW; Azimi-Sadjadi A; Brody JR; Pishvaian MJ
Mol Cancer Ther; 2019 Nov; 18(11):1899-1908. PubMed ID: 31676541
[TBL] [Abstract][Full Text] [Related]
38. Interaction between HER2 and ATM predicts poor survival in bladder cancer patients.
Albarakati N; Al-Shareeda A; Ramadan M; Al-Sowayan B; Negm O; Nedjadi T
J Cell Mol Med; 2022 Oct; 26(19):4959-4973. PubMed ID: 36056635
[TBL] [Abstract][Full Text] [Related]
39. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
40. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
